Critical Advantages
Core Technology System From Data Integration to Mechanistic Insight
Our precision medicine foundation is centred on multi-omics data integration and the interpretability of biological mechanisms, establishing a technology framework that spans macro-to-micro scales.
Multi-Omics Data Integration Platform Transcending Traditional Dimensions
Building upon original imaging, pathology, and genomics data, our platform now incorporates:
Epigenomics:
Identifies early-stage tumour-specific epigenetic variations based on cfDNA methylation patterns (e.g., 5mC/6mb end motif profiles). For instance, our model distinguishes benign from malignant pulmonary nodules, achieving an AUC of 0.923.
Radiomics-Genomics Mapping:
Correlates millimetre-scale imaging features (e.g., MRI textures) with underlying gene expression pathways (e.g., immune activation, tumour proliferation signals), imbuing imaging-based AI with biological interpretability. Glioma imaging features, for example, can be classified into "immune/proliferation/therapy-responsive" phenotypes.
Dynamic Monitoring Data Streams:
Integrates liquid biopsy–derived ctDNA, longitudinal imaging follow-up, and other real-time data streams to model tumour evolutionary trajectories, enabling early detection of clonal evolution and emerging drug resistance.
Interpretable AI From Black-Box Prediction to Biological Mechanism Transparency
Multi-Omics Feature Attribution Analysis:
Utilises interpretable algorithms such as SHAP and DeepLIFT to quantify the contribution of clinical, imaging, and genomic features to decision-making, highlighting key drivers for clinicians.
Pathological Mechanism Visualisation:
Links AI-identified imaging features (e.g., tumour border characteristics) with corresponding gene pathways (e.g., EGFR-mutation-related angiogenesis), generating a dual-view “imaging–genetic” diagnostic report to help clinicians understand the biological rationale behind AI-derived insights.
Precision Medicine Product Portfolio From Auxiliary Tool to Decision-Making Partner
We are upgrading the clinical experience by providing integrated decision support.
Ruiying – Precision
Radiomics-Driven Non-Invasive Prediction of Molecular Phenotypes
Molecular Subtype Inference:
- Uses CT/MRI radiomic features
- to predict EGFR mutations in lung cancer
- and IDH mutation status in glioma
- enabling non-invasive alternatives to partial biopsies.
Treatment Response Early Warning:
- Monitors dynamic radiomic changes
- to provide early alerts of drug resistance risk
- typically 1–2 months earlier than RECIST standards
- for solid tumours.
Zhice – Precision
Dynamic Scenario Simulation via Digital TwinsRadiomics-Driven Non-Invasive Prediction of Molecular Phenotypes
Multi-Omics Digital Twin:
- Integrates genomic profiles
- and real-world efficacy data
- to construct personalised PK/PD models
- simulating tumour shrinkage rates and toxicity risks.
Evidence-Based Knowledge Graph Expansion:Drug Resistance Evolution Tracking:
- Incorporates advanced therapies
- (e.g., radiopharmaceuticals, immunotherapy biomarkers such as TMB/MSI-H) and links them
- to NCCN/CSCO guideline frameworks.
RuiGu – Precision
Multimodal Integrated Monitoring of Efficacy and Drug Resistance
MRD Early Warning:
- Combines ctDNA clearance rates
- with radiomic features
- to build a minimal residual disease (MRD) prediction model
Drug Resistance Evolution Tracking:
- Dynamically monitors resistance mutations (e.g., EGFR T790M)
- via liquid biopsy
- and correlates them with imaging features
- such as emerging necrotic regions
Precision Medicine Ecosystem Strategy Collaborative Win–Win and Technological Inclusivity
Our strategy ensures seamless integration across technologies and broad accessibility for clinical partners and patients alike.
Vertical Ecosystem Collaboration
Co-Development with Pharmaceutical Companies:
We collaborate with pharmaceutical partners to co-develop companion diagnostic solutions, such as predicting targeted drug efficacy based on patient mutation abundance, to optimise clinical trial enrolment and therapeutic precision.
Interoperability with Device Manufacturers:
We ensure seamless compatibility with leading precision medicine equipment (e.g., GE Healthcare’s MAX Apollo PET/CT and Oxford Nanopore sequencers), enabling automated and structured multi-modal data acquisition across clinical and research environments.
Grassroots Precision Medicine Accessibility Strategy
Lightweight Solutions:
Developing edge-computing versions tailored for primary and regional hospitals, supporting offline operation of radiomics analysis models to enhance accessibility and reduce infrastructure dependence.
Integration with POCT Devices:
Collaborating with point-of-care testing (POCT) device manufacturers to enable rapid and precise screening in resource-limited settings, promoting equitable access to precision diagnostics.
Core Technologies
Our suite of modular platforms supports rapid, intelligent, and scalable lab operations.
Automated Diagnostic
Platforms
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
AI-Driven Laboratory
Analysis
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
Biotech Integration
Tools
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
Cloud-Connected Medical
Instruments
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
Secure Data Infrastructure for
Lab Environments
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore